New York, United States
Gilgamesh Pharmaceuticals is a clinical-stage biotech company founded in 2019 in the United States. The company's vision is to reshape how mental illnesses are treated, focusing on rapid-acting and durable therapies targeting the fundamental drivers of disease rather than symptom management. Gilgamesh achieves this by designing best-in-class new chemical entities (NCEs) optimized for safety, efficacy, and patient access.
With its recent $14.00M grant investment on 14 March 2024 from the National Institute on Drug Abuse (NIDA), Gilgamesh Pharmaceuticals demonstrates strong support from notable investors and government agencies as it advances its pioneering approach to mental healthcare.
The company operates in the biotechnology, healthcare, and pharmaceutical industries, positioning itself at the forefront of innovation in mental health treatment.
